Advisory Services Network’s Iovance Biotherapeutics IOVA Stock Holding History

Advisory Services Network’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.7K	Buy	+8,449	New	+$27K	﹤0.01%	2959
2025 Q4	–	Sell	-10,000	Closed	-$21.7K	–	3053
2025 Q3	$21.7K	Buy	+10,000	New	+$23.6K	﹤0.01%	2915
2022 Q2	–	Sell	-6,425	Closed	-$107K	–	1436
2022 Q1	$107K	Buy	+6,425	New	+$99.4K	﹤0.01%	1397
2020 Q4	–	Sell	-100	Closed	-$3K	–	3490
2020 Q3	$3K	Buy	+100	New	+$3.07K	﹤0.01%	2960

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Advisory Services Network's IOVA Position: Q1 2026 in Review

Advisory Services Network opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 8,449 shares worth $29.7K. The stake represents ﹤0.01% of the portfolio and ranks #2959 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in IOVA as recently as Q3 2025.

Advisory Services Network first reported a position in IOVA in Q3 2020 and has held it in 4 quarters since. The position peaked at $107K in Q1 2022. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Advisory Services Network held 8,449 shares of Iovance Biotherapeutics worth $29.7K as of Q1 2026.
Iovance Biotherapeutics was a new Advisory Services Network position in Q1 2026.
Iovance Biotherapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #2959 holding.
Advisory Services Network first reported a position in Iovance Biotherapeutics in Q3 2020 and has held it in 4 quarters since.
Advisory Services Network's Iovance Biotherapeutics position peaked at $107K in Q1 2022.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.